bristol myers-squibb
“Underwhelming” drug data devastates Nektar, shares fall by 42%
June 5, 2018Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …
New formulary ‘bank’ to aid research into combination therapies
January 11, 2017Medical Communications, Research and Development 21st Century Cures Act, Bristol-Myers Squibb, Eli Lilly, Joe Biden, Obama, bristol myers-squibb, combination therapy
As part of the wider ‘cancer moonshot’ initiative, confirmed by the signing of the 21st Century Cures Act by Obama, …
Giovanni Caforio to be made chairman of the board at BMS
January 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb
Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position …
Opdivo first PD-1 inhibitor given European approval for haematological cancer
November 25, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb
Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …
BMS lung cancer drug scores in Phase II
October 31, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo
Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
